Issues related to drug pricing; Issues related to H.R. 1227/S. 475 - Alternatives to PAIN Act.
2025 · 4th Quarter (Oct 1 - Dec 31)
VERTEX PHARMACEUTICALS
Filed by TIBER CREEK GROUP.
Open official filingSource-reported fields
Filing overview
- Type
- 4th Quarter - Report
- Posted
- Jan 17, 2026
- Income
- $60,000.00
- Expenses
- Not reported
- Registrant
- TIBER CREEK GROUP
- Client
- VERTEX PHARMACEUTICALS
- Filing UUID
- 4794c2aa-05ed-4aee-8504-e393548ddd3c
- Termination date
- Not reported
Literal source text
Lobbying issues and bill citations
Issues related to opioid alternatives; Issues related to the National Defense Authorization Act for Fiscal Year 2026 (PL 119-60).
Relationship and amount limits
Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.